Indaptus Therapeutics, INC. (INDP) — 8-K Filings

8-K Filings (23)

• Indaptus Therapeutics Files 8-K on Officer Changes and Exhibits — Apr 23, 2026 Risk: medium
  Indaptus Therapeutics, Inc. filed an 8-K on April 23, 2026, reporting changes in directors or officers and compensatory arrangements. The filing also includes f
• 8-K Filing — Apr 3, 2026
• Indaptus Therapeutics Reports Key Corporate Events — Dec 23, 2025 Risk: medium
  Indaptus Therapeutics, Inc. filed an 8-K on December 22, 2025, reporting several material events. These include entering into a material definitive agreement, u
• Indaptus Therapeutics Files 8-K — Sep 4, 2025 Risk: low
  Indaptus Therapeutics, Inc. filed an 8-K on September 4, 2025, reporting on other events and financial statements. The company, formerly known as Intec Parent I
• Indaptus Therapeutics Files 8-K on Financials — Aug 13, 2025 Risk: low
  Indaptus Therapeutics, Inc. filed an 8-K on August 13, 2025, reporting on its results of operations and financial condition. The filing includes financial state
• Indaptus Therapeutics Files 8-K on Equity Sales & Shareholder Votes — Jul 29, 2025 Risk: medium
  Indaptus Therapeutics, Inc. filed an 8-K on July 29, 2025, reporting unregistered sales of equity securities and submission of matters to a vote of security hol
• Indaptus Therapeutics Files 8-K Under 'Other Events' — Jul 16, 2025 Risk: low
  Indaptus Therapeutics, Inc. filed an 8-K on July 16, 2025, reporting an event on July 14, 2025. The filing is categorized under 'Other Events' and does not spec
• Indaptus Therapeutics Files 8-K with Financial Obligations — Jul 1, 2025 Risk: medium
  On June 30, 2025, Indaptus Therapeutics, Inc. entered into a material definitive agreement, creating a direct financial obligation. The company also reported un
• Indaptus Therapeutics Files 8-K on Security Holder Rights — Jun 26, 2025 Risk: medium
  Indaptus Therapeutics, Inc. filed an 8-K on June 26, 2025, reporting material modifications to security holder rights and amendments to its articles of incorpor
• Indaptus Therapeutics Files 8-K: New Obligations & Equity Sales — Jun 13, 2025 Risk: medium
  On June 12, 2025, Indaptus Therapeutics, Inc. entered into a material definitive agreement, likely related to financing or operations, as indicated by the filin
• Indaptus Therapeutics Files 8-K — Jun 11, 2025 Risk: low
  Indaptus Therapeutics, Inc. filed an 8-K on June 11, 2025, reporting on matters submitted to a vote of security holders and financial statements. The filing doe
• Indaptus Therapeutics Files 8-K on Financials — Mar 13, 2025 Risk: low
  Indaptus Therapeutics, Inc. filed an 8-K on March 13, 2025, reporting on its results of operations and financial condition. The filing includes financial statem
• Indaptus Therapeutics Files 8-K on Agreements — Feb 12, 2025 Risk: medium
  On February 12, 2025, Indaptus Therapeutics, Inc. filed an 8-K report detailing a material definitive agreement and unregistered sales of equity securities. The
• Indaptus Therapeutics Fails Nasdaq Listing Standards — Jan 31, 2025 Risk: high
  Indaptus Therapeutics, Inc. filed an 8-K on January 31, 2025, to report its failure to meet the continued listing standards of the Nasdaq Capital Market. The co
• Indaptus Therapeutics Files 8-K: Material Agreement & Equity Sales — Jan 14, 2025 Risk: medium
  On January 12, 2025, Indaptus Therapeutics, Inc. entered into a material definitive agreement, the details of which are not fully disclosed in this filing. The
• Indaptus Therapeutics Files 8-K: Material Agreement & Equity Sales — Nov 22, 2024 Risk: medium
  Indaptus Therapeutics, Inc. announced on November 22, 2024, that it entered into a material definitive agreement. The company also reported on unregistered sale
• Indaptus Therapeutics Terminates Merger with 03 Life Sciences — Oct 22, 2024 Risk: medium
  On October 17, 2024, Indaptus Therapeutics, Inc. announced the termination of its previously announced merger agreement with 03 Life Sciences, Inc. The terminat
• Indaptus Therapeutics Files 8-K: Material Agreement & Equity Sales — Aug 8, 2024 Risk: medium
  On August 7, 2024, Indaptus Therapeutics, Inc. entered into a Material Definitive Agreement, the specifics of which are not detailed in this filing. The company
• Indaptus Therapeutics Holds Annual Meeting, Elects Directors — Jun 7, 2024 Risk: low
  Indaptus Therapeutics, Inc. announced on June 6, 2024, that it held its 2024 Annual Meeting of Stockholders. During the meeting, stockholders elected two Class
• Indaptus Therapeutics Files 8-K — May 22, 2024 Risk: low
  Indaptus Therapeutics, Inc. filed an 8-K on May 22, 2024, reporting an event under 'Other Events'. The company, formerly known as Intec Parent Inc. until April
• Indaptus Therapeutics to be Acquired by 03 Life Sciences — Mar 25, 2024 Risk: medium
  Indaptus Therapeutics, Inc. announced on March 25, 2024, that it has entered into a definitive agreement to be acquired by 03 Life Sciences. The transaction is
• Indaptus Therapeutics Relocates HQ — Mar 4, 2024 Risk: low
  On March 4, 2024, Indaptus Therapeutics, Inc. filed an 8-K report. The filing indicates a change in the company's principal executive offices to 3 Columbus Circ
• Indaptus Therapeutics Files Routine 8-K; No Major Changes Reported — Jan 23, 2024
  Indaptus Therapeutics, Inc. filed an 8-K on January 23, 2024, reporting an event on January 22, 2024. This filing is a routine current report, indicating no maj

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX